Your browser doesn't support javascript.
loading
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Veeraraghavan, J; De Angelis, C; Mao, R; Wang, T; Herrera, S; Pavlick, A C; Contreras, A; Nuciforo, P; Mayer, I A; Forero, A; Nanda, R; Goetz, M P; Chang, J C; Wolff, A C; Krop, I E; Fuqua, S A W; Prat, A; Hilsenbeck, S G; Weigelt, B; Reis-Filho, J S; Gutierrez, C; Osborne, C K; Rimawi, M F; Schiff, R.
  • Veeraraghavan J; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center.
  • De Angelis C; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center.
  • Mao R; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center.
  • Wang T; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center; Departments of Medicine.
  • Herrera S; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center; Pathology, Baylor College of Medicine, Houston, USA.
  • Pavlick AC; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center.
  • Contreras A; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center; Pathology, Baylor College of Medicine, Houston, USA.
  • Nuciforo P; Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Mayer IA; Medicine, Hematology/Oncology, Vanderbilt University, Nashville.
  • Forero A; Medicine, University of Alabama at Birmingham, Birmingham.
  • Nanda R; Medicine, University of Chicago, Chicago.
  • Goetz MP; Department of Oncology, Mayo Clinic, Rochester.
  • Chang JC; Houston Methodist Cancer Center, Houston Methodist Hospital, Houston.
  • Wolff AC; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore.
  • Krop IE; Department of Medicine, Dana-Farber Cancer Institute, Boston.
  • Fuqua SAW; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center.
  • Prat A; Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Hilsenbeck SG; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center; Departments of Medicine.
  • Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York.
  • Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York.
  • Gutierrez C; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center; Pathology, Baylor College of Medicine, Houston, USA.
  • Osborne CK; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center; Departments of Medicine; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, USA.
  • Rimawi MF; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center; Departments of Medicine.
  • Schiff R; Lester and Sue Smith Breast Center; Dan L. Duncan Comprehensive Cancer Center; Departments of Medicine; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, USA. Electronic address: rschiff@bcm.edu.
Ann Oncol ; 30(6): 927-933, 2019 06 01.
Article en En | MEDLINE | ID: mdl-30903140
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Año: 2019 Tipo del documento: Article